The Access to Medicine Index 2008 was the first Index of its kind to track corporate governance of twenty of the world's largest pharmaceutical companies, including three generics companies, on their efforts to increase universal access to medicine. Companies were ranked on 28 indicators and 8 main criteria which in turn affected their rating according to overall performance.
Click through the Access to Medicine Index 2008 to see how companies ranked during the first Index.
| 1 | GlaxoSmithKline PLC | 4.5 | |
| 2 | Novo Nordisk A/S | 3.9 | |
| 3 | Merck & Company Inc. | 3.9 | |
| 4 | Novartis AG | 3.9 | |
| 5 | Sanofi-Aventis | 3.9 | |
| 6 | Astrazeneca PLC | 3.7 | |
| 7 | Roche Holdings Ltd. | 3.6 | |
| 8 | Johnson & Johnson | 3.6 | |
| 9 | Bayer Schering Pharma AG | 3.5 | |
| 10 | Eli Lilly & Company | 3.5 | |
| 11 | Bristol-Myers Squibb Comp. | 3.0 | |
| 12 | Abbott Laboratories Inc. | 2.9 | |
| 13 | Merck Kgaa AG | 2.7 | |
| 14 | Cipla Ltd. | 2.7 | |
| 15 | Gilead Sciences Inc. | 2.7 | |
| 16 | Ranbaxy Laboratories Ltd. | 2.6 | |
| 17 | Pfizer Inc. | 2.5 | |
| 18 | Wyeth | 2.1 | |
| 19 | Teva Pharmaceutical Ind. Ltd. | 1.8 | |
| 20 | Schering-Plough Corp. | 1.3 |
| 1 | Novo Nordisk A/S |
|
5.0 |
| 2 | GlaxoSmithKline PLC |
|
5.0 |
| 3 | Astrazeneca PLC |
|
4.8 |
| 4 | Sanofi-Aventis |
|
4.6 |
| 5 | Merck & Company Inc. |
|
4.5 |
| 6 | Novartis AG |
|
4.4 |
| 7 | Bayer Schering Pharma AG |
|
4.3 |
| 8 | Roche Holdings Ltd. |
|
4.1 |
| 9 | Johnson & Johnson |
|
3.9 |
| 10 | Merck Kgaa AG |
|
3.9 |
| 11 | Abbott Laboratories Inc. |
|
3.2 |
| 12 | Eli Lilly & Company |
|
3.2 |
| 13 | Gilead Sciences Inc. |
|
3.0 |
| 14 | Pfizer Inc. |
|
3.0 |
| 15 | Bristol-Myers Squibb Comp. |
|
2.7 |
| 16 | Ranbaxy Laboratories Ltd. |
|
2.7 |
| 17 | Cipla Ltd. |
|
2.4 |
| 18 | Wyeth |
|
1.9 |
| 19 | Schering-Plough Corp. |
|
1.2 |
| 20 | Teva Pharmaceutical Ind. Ltd. |
|
1.0 |
| 1 | Eli Lilly & Company |
|
4.8 |
| 2 | GlaxoSmithKline PLC |
|
4.6 |
| 3 | Novartis AG |
|
4.2 |
| 4 | Novo Nordisk A/S |
|
4.2 |
| 5 | Merck & Company Inc. |
|
3.8 |
| 6 | Astrazeneca PLC |
|
3.8 |
| 7 | Bristol-Myers Squibb Comp. |
|
3.6 |
| 8 | Johnson & Johnson |
|
3.3 |
| 9 | Roche Holdings Ltd. |
|
3.3 |
| 10 | Ranbaxy Laboratories Ltd. |
|
3.0 |
| 11 | Bayer Schering Pharma AG |
|
3.0 |
| 12 | Cipla Ltd. |
|
3.0 |
| 13 | Pfizer Inc. |
|
2.7 |
| 14 | Abbott Laboratories Inc. |
|
2.3 |
| 15 | Merck Kgaa AG |
|
1.6 |
| 16 | Sanofi-Aventis |
|
1.6 |
| 17 | Schering-Plough Corp. |
|
1.4 |
| 18 | Teva Pharmaceutical Ind. Ltd. |
|
1.0 |
| 19 | Wyeth |
|
1.0 |
| 20 | Gilead Sciences Inc. |
|
1.0 |
| 1 | Novartis AG |
|
5.0 |
| 2 | Sanofi-Aventis |
|
5.0 |
| 3 | GlaxoSmithKline PLC |
|
5.0 |
| 4 | Roche Holdings Ltd. |
|
3.9 |
| 5 | Astrazeneca PLC |
|
3.7 |
| 6 | Cipla Ltd. |
|
3.5 |
| 7 | Abbott Laboratories Inc. |
|
3.5 |
| 8 | Ranbaxy Laboratories Ltd. |
|
3.2 |
| 9 | Johnson & Johnson |
|
3.1 |
| 10 | Bayer Schering Pharma AG |
|
3.1 |
| 11 | Eli Lilly & Company |
|
2.9 |
| 12 | Novo Nordisk A/S |
|
2.9 |
| 13 | Wyeth |
|
2.4 |
| 14 | Merck & Company Inc. |
|
2.4 |
| 15 | Gilead Sciences Inc. |
|
2.3 |
| 16 | Merck Kgaa AG |
|
2.3 |
| 17 | Pfizer Inc. |
|
2.2 |
| 18 | Bristol-Myers Squibb Comp. |
|
1.9 |
| 19 | Schering-Plough Corp. |
|
1.0 |
| 20 | Teva Pharmaceutical Ind. Ltd. |
|
1.0 |
| 1 | GlaxoSmithKline PLC |
|
3.8 |
| 2 | Gilead Sciences Inc. |
|
3.8 |
| 3 | Merck & Company Inc. |
|
3.8 |
| 4 | Johnson & Johnson |
|
3.6 |
| 5 | Merck Kgaa AG |
|
3.4 |
| 6 | Sanofi-Aventis |
|
3.4 |
| 7 | Novo Nordisk A/S |
|
3.2 |
| 8 | Bristol-Myers Squibb Comp. |
|
3.2 |
| 9 | Eli Lilly & Company |
|
3.2 |
| 10 | Bayer Schering Pharma AG |
|
3.2 |
| 11 | Teva Pharmaceutical Ind. Ltd. |
|
3.0 |
| 12 | Cipla Ltd. |
|
3.0 |
| 13 | Ranbaxy Laboratories Ltd. |
|
3.0 |
| 14 | Astrazeneca PLC |
|
2.6 |
| 15 | Wyeth |
|
2.4 |
| 16 | Roche Holdings Ltd. |
|
2.0 |
| 17 | Schering-Plough Corp. |
|
1.8 |
| 18 | Novartis AG |
|
1.6 |
| 19 | Abbott Laboratories Inc. |
|
1.0 |
| 20 | Pfizer Inc. |
|
1.0 |
| 1 | Merck & Company Inc. |
|
3.9 |
| 2 | Bayer Schering Pharma AG |
|
3.9 |
| 3 | Eli Lilly & Company |
|
3.8 |
| 4 | GlaxoSmithKline PLC |
|
3.7 |
| 5 | Novartis AG |
|
3.6 |
| 6 | Bristol-Myers Squibb Comp. |
|
3.4 |
| 7 | Johnson & Johnson |
|
3.4 |
| 8 | Sanofi-Aventis |
|
3.4 |
| 9 | Roche Holdings Ltd. |
|
3.3 |
| 10 | Merck Kgaa AG |
|
3.3 |
| 11 | Pfizer Inc. |
|
3.1 |
| 12 | Novo Nordisk A/S |
|
2.6 |
| 13 | Abbott Laboratories Inc. |
|
2.6 |
| 14 | Gilead Sciences Inc. |
|
2.5 |
| 15 | Astrazeneca PLC |
|
2.5 |
| 16 | Cipla Ltd. |
|
2.2 |
| 17 | Teva Pharmaceutical Ind. Ltd. |
|
1.8 |
| 18 | Ranbaxy Laboratories Ltd. |
|
1.6 |
| 19 | Wyeth |
|
1.4 |
| 20 | Schering-Plough Corp. |
|
1.4 |
| 1 | GlaxoSmithKline PLC |
|
4.8 |
| 2 | Novo Nordisk A/S |
|
4.8 |
| 3 | Johnson & Johnson |
|
4.5 |
| 4 | Merck & Company Inc. |
|
4.5 |
| 5 | Bristol-Myers Squibb Comp. |
|
4.3 |
| 6 | Cipla Ltd. |
|
4.2 |
| 7 | Gilead Sciences Inc. |
|
3.9 |
| 8 | Roche Holdings Ltd. |
|
3.9 |
| 9 | Ranbaxy Laboratories Ltd. |
|
3.8 |
| 10 | Teva Pharmaceutical Ind. Ltd. |
|
3.7 |
| 11 | Sanofi-Aventis |
|
3.7 |
| 12 | Astrazeneca PLC |
|
3.3 |
| 13 | Novartis AG |
|
3.3 |
| 14 | Wyeth |
|
3.1 |
| 15 | Eli Lilly & Company |
|
3.1 |
| 16 | Bayer Schering Pharma AG |
|
2.8 |
| 17 | Abbott Laboratories Inc. |
|
2.8 |
| 18 | Pfizer Inc. |
|
2.6 |
| 19 | Schering-Plough Corp. |
|
1.8 |
| 20 | Merck Kgaa AG |
|
1.8 |
| 1 | Sanofi-Aventis |
|
5.0 |
| 2 | Merck & Company Inc. |
|
5.0 |
| 3 | Roche Holdings Ltd. |
|
5.0 |
| 4 | GlaxoSmithKline PLC |
|
5.0 |
| 5 | Astrazeneca PLC |
|
5.0 |
| 6 | Bayer Schering Pharma AG |
|
4.2 |
| 7 | Novartis AG |
|
4.2 |
| 8 | Eli Lilly & Company |
|
4.2 |
| 9 | Novo Nordisk A/S |
|
4.2 |
| 10 | Wyeth |
|
3.0 |
| 11 | Abbott Laboratories Inc. |
|
3.0 |
| 12 | Johnson & Johnson |
|
3.0 |
| 13 | Merck Kgaa AG |
|
3.0 |
| 14 | Pfizer Inc. |
|
3.0 |
| 15 | Teva Pharmaceutical Ind. Ltd. |
|
1.8 |
| 16 | Bristol-Myers Squibb Comp. |
|
1.8 |
| 17 | Ranbaxy Laboratories Ltd. |
|
1.8 |
| 18 | Cipla Ltd. |
|
1.8 |
| 19 | Gilead Sciences Inc. |
|
1.8 |
| 20 | Schering-Plough Corp. |
|
1.0 |
| 1 | Abbott Laboratories Inc. |
|
5.0 |
| 2 | Eli Lilly & Company |
|
5.0 |
| 3 | Merck & Company Inc. |
|
5.0 |
| 4 | Bristol-Myers Squibb Comp. |
|
4.0 |
| 5 | Johnson & Johnson |
|
4.0 |
| 6 | Novartis AG |
|
4.0 |
| 7 | Novo Nordisk A/S |
|
4.0 |
| 8 | Bayer Schering Pharma AG |
|
4.0 |
| 9 | Pfizer Inc. |
|
3.0 |
| 10 | Ranbaxy Laboratories Ltd. |
|
3.0 |
| 11 | GlaxoSmithKline PLC |
|
3.0 |
| 12 | Astrazeneca PLC |
|
3.0 |
| 13 | Roche Holdings Ltd. |
|
3.0 |
| 14 | Sanofi-Aventis |
|
3.0 |
| 15 | Gilead Sciences Inc. |
|
2.0 |
| 16 | Wyeth |
|
2.0 |
| 17 | Merck Kgaa AG |
|
2.0 |
| 18 | Schering-Plough Corp. |
|
1.0 |
| 19 | Cipla Ltd. |
|
1.0 |
| 20 | Teva Pharmaceutical Ind. Ltd. |
|
1.0 |